Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
August 10, 2018 — Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American...
SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
July 16, 2018 — Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
June 29, 2018 — In the battle against metastatic castrate-resistant...
Technology | Focused Ultrasound Therapy | June 19, 2018
June 19, 2018 — EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
June 14, 2018 — Hitachi Medical Systems Europe has been awarded the contract to supply six...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
June 13, 2018 — A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine...
News | Brachytherapy Systems | June 07, 2018
June 7, 2018 — IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate...
New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018
May 21, 2018 — Three new studies presented at the 113th annual meeting of the American Urological Association (AUA)...
News | Radiopharmaceuticals and Tracers | May 09, 2018
May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a...
USPSTF Updates Recommendations for Prostate Cancer Screening
News | Prostate Cancer | May 09, 2018
May 9, 2018 – The U.S. Preventive Services Task Force (USPSTF) posted a...
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer. Example of an Axumin PET scan.
News | PET Imaging | February 21, 2018
February 21, 2018 — Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
New Data Examines Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
News | Prostate Cancer | December 19, 2017
December 19, 2017 — Humanetics Corp. presented data at the annual meetings of the American Society for Radiation...
Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017
November 14, 2017 — Spectronic Medical announced that new data for their MRIPlanner software, generating...
Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017
October 30, 2017 — The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing...